911 results on '"Baldus, Claudia D."'
Search Results
2. Hämatrain-Hybrid movement therapy during inpatient and outpatient hematological treatment: correlations with physical and psychological parameters
3. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
4. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
5. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
6. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
7. Prognostic impact of CEBPA mutational subgroups in adult AML
8. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
9. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
10. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
11. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma
12. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
13. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
14. FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
15. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
16. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
17. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
18. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
19. Overlapping features of therapy-related and de novo NPM1-mutated AML
20. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
21. Molekulare Diversität der akuten lymphoblastischen Leukämie: Innovationen in Diagnostik und Therapie
22. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
23. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
24. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
25. Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
26. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
27. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
28. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
29. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
30. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
31. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
32. An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse
33. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
34. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
35. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
36. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
37. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
38. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study
39. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
40. Prognostic impact of CEBPA mutational subgroups in adult AML
41. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
42. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
43. In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
44. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma
45. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
46. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia
47. Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
48. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
49. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
50. Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.